The ENTRESTO Co-Pay Program has been discontinued. As a result, financial assistance through this program is no longer available.
This communication is intended to provide notice of program discontinuation and does not provide medical advice.
Skip to main content
Important Safety Information
BOXED WARNING: FETAL TOXICITY
- When pregnancy is detected, discontinue ENTRESTO as soon as possible
- Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus
ENTRESTO is contraindicated in patients with hypersensitivity to any component...
Indication
ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
LVEF is a variable measure, so use clinical judgment in deciding whom to treat.
Click or scroll to see IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING AND INDICATION
Definitions
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction.